PepGen Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

PepGen şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-102.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-102.5%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Mar 31

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

Summary PepGen Inc. achieved positive data from the phase 2 CONNECT1 study, using PGN-EDO51 for the treatment of exon 51 skipping DMD patients; higher 10 mg/kg dosing of drug data is expected in early 2025. The global Duchenne Muscular Dystrophy treatment market size is expected to reach $8.19 billion in 2029. PGN-EDO53 is another EDO drug being developed by the company, with the goal of targeting 8% of DMD patients amenable to exon 53 skipping. Update on the use of PGN-EDODM1, in the ongoing phase 1 FREEDOM-DM1 study, expected in Q4 of 2024; Positive update could move the program towards a phase 2 trial. Read the full article on Seeking Alpha

Seeking Alpha • May 20

The Prognosis For PepGen

Summary PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months. The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51. PepGen is focused on developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, with two programs in human trials. A full investment analysis around PepGen follows in the paragraphs below. Read the full article on Seeking Alpha

Seeking Alpha • Jan 20

PepGen: Long Road Ahead

Summary PepGen is using exon skipping therapies to address muscular dystrophy conditions, specifically Duchenne muscular dystrophy (DMD) and Myotonic dystrophy type 1 (DM1). They are developing PGN-EDO51 and PGN-EDODM1. The market sizes for these therapies are estimated to be around $1.3 billion for DMD and potentially up to $4.5 billion for DM1, but there are financial and operational risks involved. Valuation doesn't offer enough of a margin of safety. Read the full article on Seeking Alpha

Analiz Makalesi • Nov 13

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Analiz Makalesi • Jul 31

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Dec 31

We Think PepGen (NASDAQ:PEPG) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: PEPG şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: PEPG şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

PepGen Piyasaya Karşı Temettü Getirisi

PEPG temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (PEPG)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.3%
Sektör Ortalaması (Biotechs)	2.4%
Analist tahmini (PEPG) (3 yıla kadar)	0%

Önemli Temettü: PEPG şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, PEPG şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: PEPG şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: PEPG herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/17 14:24
Gün Sonu Hisse Fiyatı	2026/05/15 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

PepGen Inc. 8 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Tazeen Ahmad	BofA Global Research
Debjit Chattopadhyay	Guggenheim Securities, LLC
Ananda Ghosh	H.C. Wainwright & Co.

PepGen Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

PepGen Inc., Annual General Meeting, Jun 18, 2026

New major risk - Share price stability

PepGen Plunges On Mixed Phase 2 Data, But Higher Dose Could Offer Some Relief

PepGen Inc Announces Regulatory Updates On Freedom2 Trial

Price target increased by 8.6% to US$10.86

Price target increased by 7.0% to US$10.17

Pepgen Inc. Appoints Joseph Vittiglio as Chief Business and Legal Officer, Effective December 8, 2025

Is PepGen (NASDAQ:PEPG) In A Good Position To Deliver On Growth Plans?

Price target increased by 21% to US$11.50

Price target increased by 16% to US$9.50

Price target increased by 22% to US$8.33

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $100 million.

New major risk - Share price stability

PepGen Inc.(NasdaqGS:PEPG) dropped from Russell 2500 Growth Index

Here's Why We're A Bit Worried About PepGen's (NASDAQ:PEPG) Cash Burn Situation

Pomerantz Law Firm Announces the Filing of A Class Action Against Pepgen Inc

Price target decreased by 31% to US$8.00

PepGen Inc. to Focus on Development of Promising DM1 Program Following 10 mg/Kg PGN-EDO51 Update

Price target decreased by 7.8% to US$11.80

PepGen Inc., Annual General Meeting, Jun 04, 2025

PepGen Inc. Announces Appointment of Two New Directors to Its Board

PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

New major risk - Share price stability

Pepgen Inc. Announces Positive Initial Results, Including Robust Splicing Correction, from Ongoing FREEDOM-DM1 Trial in Patients with DM1

Price target decreased by 21% to US$12.80

PepGen Inc. Announces CONNECT Program Updates

New major risk - Shareholder dilution

New minor risk - Market cap size

Insufficient new directors

Price target decreased by 9.4% to US$15.40

PepGen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate Connect2-EDO51 Phase 2 Study of PGN-EDO51 for Duchenne Muscular Dystrophy

Here's Why We're Watching PepGen's (NASDAQ:PEPG) Cash Burn Situation

Price target decreased by 13% to US$17.00

New major risk - Revenue and earnings growth

PepGen Inc. Announces Christopher Ashton to Retire from Its Board of Directors, Effective September 30, 2024

New major risk - Share price stability

PepGen Inc. Appoints Paul Streck as Executive Vice President, Head of Research & Development, Head of Research & Development

Price target decreased by 9.3% to US$19.60

PepGen (NASDAQ:PEPG) Is In A Good Position To Deliver On Growth Plans

Chief Medical Officer exercised options and sold US$61k worth of stock

PepGen: EDOs Could Enhance Dystrophin Expression Beyond Scope Of Current Treatments

PepGen Inc. Announces Positive Data from Low-Dose Cohort of Pgn-Edo51 in Ongoing Connect1-Edo51 Phase 2 Clinical Trial for Treatment of Duchenne Muscular Dystrophy

Chief Medical Officer exercised options and sold US$72k worth of stock

PepGen Inc. Appoints Afsaneh Mohebbi as SVP, Portfolio and Program Management and Dave Borah as SVP, Investor Relations and Corporate Communications

Chief Medical Officer exercised options and sold US$74k worth of stock

Pepgen Inc. Announces Executive Promotions

Insider notifies of intention to sell stock

The Prognosis For PepGen

Senior Vice President of Chemistry notifies of intention to sell stock

PepGen Inc., Annual General Meeting, Jun 20, 2024

PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1

PepGen Inc. has completed a Follow-on Equity Offering in the amount of $80.08155 million.

New minor risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 14% to US$20.00

PepGen: Long Road Ahead

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

Pepgen Inc. Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of P GN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping

Pepgen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Announces Appointment of Howard Mayer, M.D. to Board of Directors

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

New major risk - Revenue and earnings growth

PepGen Inc. Announces FDA Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)

PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company's Enhanced Delivery Oligonucleotide Platform and PGN-EDO Program at Two Medical Conferences

New major risk - Share price stability

New major risk - Revenue and earnings growth

Will PepGen (NASDAQ:PEPG) Spend Its Cash Wisely?

PepGen Inc. Provides Update on Planned Initiation of Phase 1 Study of PGN-EDODM1 in Myotonic Dystrophy Type 1

New major risk - Share price stability

Pepgen Inc. Announces Clinical Hold in the U.S. on IND Application to Initiate A Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1

PepGen Inc. to Report Q1, 2023 Results on May 11, 2023

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock